These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38011912)

  • 1. Risk of ischemic stroke associated with direct oral anticoagulants discontinuation on patients with non-valvular atrial fibrillation.
    Álvaro Thomsen T; Mesa Guadalupe J; Huerta C; de Burgos A; Cea Soriano L
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5733. PubMed ID: 38011912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
    BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims.
    Lip GYH; Noxon V; Kang A; Luo X; Atreja N; Han S; Cheng D; Jiang J; Abramovitz L; Deitelzweig S
    J Thromb Thrombolysis; 2024 Aug; 57(6):1092-1102. PubMed ID: 38698197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
    Dhamane AD; Ferri M; Keshishian A; Russ C; Atreja N; Gutierrez C; Emir B; Yuce H; Di Fusco M
    Adv Ther; 2023 Mar; 40(3):887-902. PubMed ID: 36527598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
    Lawal OD; Aronow HD; Shobayo F; Hume AL; Taveira TH; Matson KL; Zhang Y; Wen X
    Circulation; 2023 Mar; 147(10):782-794. PubMed ID: 36762560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
    Khachatryan A; Doobaree IU; Spentzouris G; Gusto G; Zawaneh Y; Mughal F; Anastassopoulou A; Manu M; Fay M
    Adv Ther; 2023 Feb; 40(2):504-520. PubMed ID: 36399317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of Patients With Ischemic Stroke With Prior Anticoagulant Therapy: Direct Oral Anticoagulants Versus Warfarin.
    Chun KH; Lee H; Hong JH; Seo KD
    J Am Heart Assoc; 2024 Aug; 13(15):e034698. PubMed ID: 39101509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.
    Jaksa A; Gibbs L; Kent S; Rowark S; Duffield S; Sharma M; Kincaid L; Ali AK; Patrick AR; Govil P; Jonsson P; Gatto N
    BMJ Open; 2022 Oct; 12(10):e064662. PubMed ID: 36253039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Efficacy and Safety Between Patients With Atrial Fibrillation Taking Direct Oral Anticoagulants or Warfarin After Direct Oral Anticoagulant Failure.
    Hsieh MT; Liu CH; Lin SH; Lin PY; Chang YM; Wang CM; Chen CH; Sung PS
    J Am Heart Assoc; 2023 Dec; 12(23):e029979. PubMed ID: 38038171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.
    Enomoto A; Mano Y; Kawano Y; Nishikawa T; Aoyama T; Sasaki Y; Nagata M; Takahashi H
    Biol Pharm Bull; 2021; 44(9):1294-1302. PubMed ID: 34471057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
    Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
    Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
    Jansson M; Själander S; Sjögren V; Björck F; Renlund H; Norrving B; Själander A
    J Thromb Thrombolysis; 2023 Apr; 55(3):415-425. PubMed ID: 36607464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m
    O'Kane CP; Avalon JCO; Lacoste JL; Fang W; Bianco CM; Davisson L; Piechowski KL
    Pharmacotherapy; 2022 Feb; 42(2):112-118. PubMed ID: 34820876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation.
    Alberts M; Zhdanava M; Pilon D; Caron-Lapointe G; Lefebvre P; Bookhart B; Kharat A
    Adv Ther; 2023 May; 40(5):2339-2354. PubMed ID: 36947331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
    Lip GYH; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Phatak H
    PLoS One; 2018; 13(4):e0195950. PubMed ID: 29709012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
    Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
    PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.
    Archontakis-Barakakis P; Li W; Kalaitzoglou D; Tzelves L; Manolopoulos A; Giannopoulos S; Giamouzis G; Giannakoulas G; Batsidis A; Palaiodimos L; Ntaios G; Lip GYH; Kokkinidis DG
    Br J Clin Pharmacol; 2022 Nov; 88(11):4663-4675. PubMed ID: 35853612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Safety and Effectiveness of Reduced Doses of Direct Acting Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation.
    Skjøth F; Larsen TB; Dun AR; Lilja M; Rahman I; Abdelgawwad K; Halvorsen S; Coleman C; Rivera M
    Am J Med; 2024 Jun; 137(6):520-528.e13. PubMed ID: 38387539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.